Ips Research Company

Oklahoma City, Oklahoma 73703

0 studies enrolling now · 110 studies all time

What they study most

ADHD, Acute Treatment of Migraine, Adenoviral Conjunctivitis, Adult Attention Deficit Hyperactivity Disorder, Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Alzheimer's Disease, Alzheimers Disease, Anxiety Disorder, Anxiety, Separation, Asthma, Attention Deficit Disorder With Hyperactivity

Studies at this site

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine — Recruiting now
Randomized Study in Children and Adolescents With Migraine: Acute Treatment — Recruiting now
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Stopped early
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Stopped early
A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy — Completed
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression — Completed
A Study of JNJ-61393215 in the Treatment of Depression — Completed
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression — Completed
A Study of JZP150 in Adults With Posttraumatic Stress Disorder — Completed
Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions — Completed
Randomized Trial of Adult Participants With Generalized Anxiety Disorder — Completed
A Study of ARRY-502 in Patients With Persistent Asthma — Completed
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children — Stopped early
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder — Completed
Clostridium Difficile Vaccine Efficacy Trial — Completed
Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) — Completed
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder — Completed
A Study in Patients With Trichotillomania — Completed
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting — Completed
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl — Completed
Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder — Completed
Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) — Completed
SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms — Completed
Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant — Completed
SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study — Completed
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) — Completed
Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate — Completed
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP) — Completed
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo — Stopped early
Open Label Extension in Adults With Binge Eating Disorder (BED) — Completed
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo — Completed
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study) — Completed
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder — Completed
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) — Completed
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) — Stopped early
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) — Completed
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years — Completed
Dasotraline Pediatric ADHD Study — Completed
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome — Completed
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder — Completed
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation — Stopped early